10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for TXG. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: TXG is a Buy candidate.
TXG stock price ended at $61.65 on 水曜日, after rising 2.78%
On the latest trading day Sep 02, 2026, the stock price of TXG rose by 2.78%, climbing from $60.24 to $61.65. Throughout the session, the stock experienced a volatility of 6.87%, with prices fluctuating between a daily low of $59.41 and a high of $63.49. Alongside this price increase, trading volume also rose by 358.7K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.6M shares were traded, amounting to a market value of approximately $7.8B.